FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine. What is presented is a vaccine against pneumonia caused by Streptococcus pneumoniae, on the basis of a hybrid protein described by SEQ ID NO:1, containing fragments of the proteins Streptococcus pneumoniae PspA, Sprl 895, PsaA, as well as the ingredients of flagellin as an adjuvant, connected by flexible bridges.
EFFECT: invention provides the effective prevention and therapy of pneumonia ensured by the fact that the vaccine hybrid protein is composed of various immunogenic epitopes eliciting a specific immune response with formed immunological memory.
4 dwg, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| LIVE VACCINE BASED ON ENTEROCOCCUS FAECIUM L3 PROBIOTIC STRAIN FOR PREVENTION OF INFECTION CAUSED BY STREPTOCOCCUS PNEUMONIE | 2018 |
|
RU2701733C1 |
| INFLUENZA VIRUS STRAIN INFLUBACT-H7/PSPA FOR THE PRODUCTION OF A COMBINED VACCINE AGAINST INFLUENZA A VIRUS AND BACTERIAL PNEUMONIA CAUSED BY STREPTOCOCCUS PNEUMONIAE | 2021 |
|
RU2776196C1 |
| RECOMBINANT PLASMID DNA pSp-raPLY ENCODING THE SYNTHESIS OF RECOMBINANT ATOXIC PNEUMOLYSIN PROTEIN STREPTOCOCCUS PNEUMONIAE, STRAIN OF ESCHERICHIA coli M15/pSp-raPLY BEING A PRODUCER OF RECOMBINANT ATOXIC FORM OF PNEUMOLYSIN, AND PRODUCTION OF SAID PROTEIN FOR DEVELOPING A VACCINE PRODUCT FOR PREVENTING PNEUMOCOCCAL INFECTIONS | 2021 |
|
RU2782598C1 |
| IMMUNOBIOLOGICAL AGENT BASED ON RECOMBINANT PROTEIN FOR PREVENTING PNEUMOCOCCAL INFECTION | 2024 |
|
RU2823752C1 |
| VACCINES AND COMPOSITION AGAINST STREPTOCOCCUS PNEUMONIAE | 2012 |
|
RU2623174C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING ATTENUATED Streptococcus pneumoniae STRAINS, AND ITS APPLICATION | 2018 |
|
RU2772131C2 |
| MULTIVALENT COMPOSITION BASED ON PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATES | 2013 |
|
RU2606152C1 |
| STREPTOCOCCUS PNEUMONIAE VACCINES AND COMPOSITIONS | 2010 |
|
RU2580299C2 |
| POLYVALENT COMPOSITION CONTAINING PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATES | 2013 |
|
RU2605834C2 |
| HYBRID PROTEIN-BASED POLYVALENT INFLUENZA VACCINE | 2013 |
|
RU2531235C2 |
